The Evolving Role of (18)F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer

Positron emission tomography/computed tomography (PET/CT) is widely used in prostate cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions early. (18)F-FDG is the most used tracer for oncologic imaging, but it has limitations in detecting early-stage prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Kai, Liu, Bo, Zhou, Xiang, Ji, Yiyi, Chen, Lei, Wang, Qi, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358601/
https://www.ncbi.nlm.nih.gov/pubmed/34395251
http://dx.doi.org/10.3389/fonc.2021.683793
Descripción
Sumario:Positron emission tomography/computed tomography (PET/CT) is widely used in prostate cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions early. (18)F-FDG is the most used tracer for oncologic imaging, but it has limitations in detecting early-stage prostate cancer. (68)Ga-PSMA is a new tracer that has high specificity and sensibility in detecting local and metastatic tumors. But with the progression of prostate cancer, the enhancement of glucose metabolism in progressive prostate cancer provides a chance for (18)F-FDG. This review focuses on PET/CT in the detection and prognosis of prostate cancer, summarizing the literature on (18)F-FDG and (68)Ga-PSMA in prostate cancer and highlighting that (18)F-FDG has advantages in detecting local recurrence, visceral and lymph node metastases compared to (68)Ga-PSMA in partial progressive prostate cancer and castration-resistant prostate cancer patients. We emphasize (18)F-FDG PET/CT can compensate for the weakness of (68)Ga-PSMA PET/CT in progressive prostate cancer.

Ejemplares similares